Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Shares Continue Slide

Shares in Stratagene fell 15 percent for the week ended Tuesday. The firm's shares led decliners in the BCW Index for the third week in a row. Since the beginning of May, Stratagene's shares have lost nearly half their value, though the reasons for the drop remain unclear (see related article).

Molecular Devices led the eight stocks that gained value during the tracking period, closing up 5.2 percent for the week. Overall, the Index gained .3 percent. In comparison, the Dow Jones Industrial Average fell .8 percent, the Nasdaq dipped .1 percent, and the Nasdaq Biotech Index gained .3 percent.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(June 6, 2006)
Last Price
(May 30, 2006)
% change
Agilent
A
34.04
34.08
-0.1
Applied Biosystems
ABI
30.52
29.12
4.8
Beckman
BEC
55.07
55.15
-0.1
Bio-Rad
BIO
65.31
66.83
-2.3
Bruker
BRKR
5.31
5.41
-1.8
Fisher Scientific
FSH
73.75
74.40
-0.9
GE
GE
34.55
34.05
1.5
Harvard Bio
HBIO
4.10
4.15
-1.2
Invitrogen
IVGN
64.24
64.08
0.2
Molecular Devices
MDCC
29.40
27.94
5.2
PerkinElmer
PKI
20.15
20.24
-0.4
Qiagen
QGEN
13.80
13.91
-0.8
Sigma
SIAL
69.14
68.97
0.2
Stratagene
STGN
6.08
7.16
-15.1
Thermo
TMO
36.81
36.57
0.7
Waters
WAT
43.54
41.78
4.2
BCW Index Average
36.61
36.49
0.3
The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.